These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 19695680)

  • 1. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
    Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
    Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.
    Vranic S; Gurjeva O; Frkovic-Grazio S; Palazzo J; Tawfik O; Gatalica Z
    Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):413-6. PubMed ID: 21436679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].
    Liu ZB; Wu J; Ping B; Feng LQ; Shen ZZ; Shao ZM
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):610-4. PubMed ID: 19102940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
    Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
    Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.
    Hussein YR; Sood AK; Bandyopadhyay S; Albashiti B; Semaan A; Nahleh Z; Roh J; Han HD; Lopez-Berestein G; Ali-Fehmi R
    Hum Pathol; 2012 Oct; 43(10):1638-44. PubMed ID: 22436627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
    Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
    Zhao P; Lu Y; Jiang X; Li X
    Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast.
    Barısık NO; Keser SH; Gul AE; Sensu S; Kandemir NO; Kucuk HF; Gumus M; Karadayı N
    Med Oncol; 2011 Sep; 28(3):703-8. PubMed ID: 20354817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
    Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
    PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
    Fadare O; Wang SA; Hileeto D
    Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMP3 expression in triple-negative breast carcinoma.
    Sidoni A; Cartaginese F
    Hum Pathol; 2010 Sep; 41(9):1355-6; author reply 1356-7. PubMed ID: 20708461
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic markers in triple-negative breast cancer.
    Rakha EA; El-Sayed ME; Green AR; Lee AH; Robertson JF; Ellis IO
    Cancer; 2007 Jan; 109(1):25-32. PubMed ID: 17146782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal-like immunophenotype markers and prognosis in early breast cancer.
    Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
    Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma.
    Serrero G; Hawkins DM; Yue B; Ioffe O; Bejarano P; Phillips JT; Head JF; Elliott RL; Tkaczuk KR; Godwin AK; Weaver J; Kim WE
    Breast Cancer Res; 2012 Feb; 14(1):R26. PubMed ID: 22316048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
    Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
    Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
    Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.